文献速递肝病消化道肿瘤与早癌

整合基因组与实验分析发现具有治疗潜力的CPS1缺陷型肝细胞癌亚型

Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.
PubMed 文献 · Hepatology · 2021-10-11

该研究通过分析TCGA泛癌代谢基因数据及多个HCC队列,识别出尿素循环下调且CPS1缺陷的HCC亚型,临床预后差。机制上CPS1缺陷致氨蓄积,激活AMPK-FAO通路,为细胞增殖供能并增强化疗耐药,阻断FAO可能使该亚型患者获益。

要点

  • 尿素循环在肝癌中下调,CPS1缺陷型HCC亚型临床预后差。
  • CPS1缺陷通过氨蓄积激活AMPK-FAO通路,增强增殖与化疗耐药。
  • 依莫克西阻断FAO可能对CPS1缺陷型HCC有治疗潜力。

核心结论

  • 研究证明尿素循环障碍与HCC干性直接相关,并通过大数据挖掘定义了CPS1缺陷型HCC亚型。
  • 靶向FAO可能为该亚型HCC提供治疗思路。

研究设计与样本

  • 研究基于TCGA的16种癌症类型7,764个肿瘤样本的泛癌代谢基因差异表达分析。
  • 分析HCC Expression Atlas数据库7个队列2,596例HCC及院内肝切除队列17,444例HCC的基因表达数据。
  • 采用体外和体内验证、液相色谱-质谱及Seahorse分析,并使用皮下异种移植瘤模型和患者来源类器官。

主要发现

  • 尿素循环具有肝脏特异性且在HCC中下调。
  • 识别出CPS1缺陷型HCC亚型,临床预后差。
  • 尿素循环障碍导致三羧酸循环减速,CPS1缺陷所致氨过量通过磷酸化AMPK激活FAO。
  • FAO通过激活FOXM1为细胞增殖提供充足ATP并增强HCC细胞化疗耐药。

临床怎么用

  • 对CPS1缺陷型HCC患者,可考虑靶向FAO(如依莫克西)作为潜在治疗策略。
  • CPS1缺陷型HCC亚型临床预后差,需加强监测与个体化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Metabolic reprogramming plays an important role in tumorigenesis. However, the metabolic types of different tumors are diverse and lack in-depth study. Here, through analysis of big databases and clinical samples, we identified a carbamoyl phosphate synthetase 1 (CPS1)-deficient hepatocellular carcinoma (HCC) subtype, explored tumorigenesis mechanism of this HCC subtype, and aimed to investigate metabolic reprogramming as a target for HCC prevention. APPROACH AND RESULTS: A pan-cancer study involving differentially expressed metabolic genes of 7,764 tumor samples in 16 cancer types provided by The Cancer Genome Atlas (TCGA) demonstrated that urea cycle (UC) was liver-specific and was down-regulated in HCC. A large-scale gene expression data analysis including 2,596 HCC cases in 7 HCC cohorts from Database of HCC Expression Atlas and 17,444 HCC cases from in-house hepatectomy cohort identified a specific CPS1-deficent HCC subtype with poor clinical prognosis. In vitro and in vivo validation confirmed the crucial role of CPS1 in HCC. Liquid chromatography-mass spectrometry assay and Seahorse analysis revealed that UC disorder (UCD) led to the deceleration of the tricarboxylic acid cycle, whereas excess ammonia caused by CPS1 deficiency activated fatty acid oxidation (FAO) through phosphorylated adenosine monophosphate-activated protein kinase. Mechanistically, FAO provided sufficient ATP for cell proliferation and enhanced chemoresistance of HCC cells by activating forkhead box protein M1. Subcutaneous xenograft tumor models and patient-derived organoids were employed to identify that blocking FAO by etomoxir may provide therapeutic benefit to HCC patients with CPS1 deficiency. CONCLUSIONS: In conclusion, our results prove a direct link between UCD and cancer stemness in HCC, define a CPS1-deficient HCC subtype through big-data mining, and provide insights for therapeutics for this type of HCC through targeting FAO.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wu T, Luo G, Lian Q, et al. Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis. Hepatology. 2021. PMID: 34343359. doi:10.1002/hep.32088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。